Stockscreener 앱 받기
33.53
0.47%
-0.16
시간 외 거래:
33.53
전일 마감가:
$33.69
열려 있는:
$34.41
하루 거래량:
1.08M
Relative Volume:
0.69
시가총액:
$5.45B
수익:
$1.51B
순이익/손실:
$333.35M
주가수익비율:
17.19
EPS:
1.95
순현금흐름:
$315.22M
1주 성능:
-1.15%
1개월 성능:
-1.50%
6개월 성능:
+21.79%
1년 성능:
+23.05%
1일 변동 폭
$33.50
$34.45
1주일 범위
$33.22
$35.41
52주 변동 폭
$22.90
$36.45
Alkermes Plc Stock (ALKS) Company Profile
명칭
Alkermes Plc
전화
00-353-1-772-8000
주소
CONNAUGHT HOUSE, DUBLIN 4
ALKS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
33.53 | 5.45B | 1.51B | 333.35M | 315.22M | 1.95 |
|
ZTS
Zoetis Inc
|
165.02 | 73.07B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.14 | 47.43B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.12 | 45.72B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.49 | 17.75B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.75 | 14.03B | 612.78M | -86.37M | -62.91M | -0.87 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2025-03-04 | 업그레이드 | UBS | Sell → Neutral |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-11-05 | 업그레이드 | Stifel | Hold → Buy |
| 2024-06-17 | 개시 | TD Cowen | Buy |
| 2024-03-19 | 개시 | Robert W. Baird | Outperform |
| 2024-02-20 | 다운그레이드 | UBS | Neutral → Sell |
| 2023-11-20 | 재개 | JP Morgan | Neutral |
| 2023-10-24 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-10-17 | 개시 | UBS | Neutral |
| 2022-11-03 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-08-16 | 개시 | Piper Sandler | Neutral |
| 2022-04-22 | 재개 | Goldman | Buy |
| 2022-04-20 | 개시 | Goldman | Buy |
| 2022-01-27 | 업그레이드 | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | 개시 | Citigroup | Neutral |
| 2021-10-07 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-09-02 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-10-15 | 업그레이드 | Mizuho | Neutral → Buy |
| 2020-07-30 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-02-14 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | 재확인 | H.C. Wainwright | Neutral |
| 2020-02-14 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2020-01-31 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | 업그레이드 | Goldman | Sell → Neutral |
| 2019-05-31 | 개시 | H.C. Wainwright | Neutral |
| 2019-05-01 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2018-12-19 | 다운그레이드 | Goldman | Neutral → Sell |
| 2018-12-14 | 개시 | Wolfe Research | Underperform |
| 2018-12-13 | 다운그레이드 | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | 개시 | Piper Jaffray | Neutral |
| 2018-08-07 | 개시 | Stifel | Hold |
| 2018-06-21 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | 개시 | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | 업그레이드 | Citigroup | Neutral → Buy |
| 2018-05-11 | 개시 | BofA/Merrill | Buy |
모두보기
Alkermes Plc 주식(ALKS)의 최신 뉴스
Deutsche Bank Adjusts Alkermes Public Price Target to $52 From $40, Maintains Buy Rating - Marketscreener.com
What 5 Analyst Ratings Have To Say About Alkermes - Benzinga
New National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder - PR Newswire
Will Alkermes' Proprietary Drugs Aid Growth Amid Stiff Competition? - MSN
Mural Oncology stock plunges on trial halt (MURA:NASDAQ) - Seeking Alpha
Liposomal Drug Delivery Market Detailed In New Research Report - openPR
First Week of November 21st Options Trading For Alkermes (ALKS) - Nasdaq
Controlled Release Drug Delivery Market to Witness Massive - openPR
Alkermes price target raised to $35 from $34 at BofA - MSN
Where are the Opportunities in (ALKS) - Stock Traders Daily
Insider Sale at Alkermes PLC: EVP R&D, Chief Medical Officer Cra - GuruFocus.com
Why Is Alkermes (ALKS) Down 6.6% Since Last Earnings Report? - Yahoo Finance
Is Alkermes plc (ALKS) the Best Healthcare Stock For Long-Term Investment? - Insider Monkey
Alkermes PLC Reports Q4 Revenue of $430 Million, Beating Estimat - GuruFocus.com
Alkermes' (NASDAQ:ALKS) investors will be pleased with their splendid 140% return over the last five years - Yahoo Finance
Alkermes (NASDAQ:ALKS) shareholders have earned a 19% CAGR over the last five years - Simply Wall St
Alkermes Facing Near-Term Headwinds Across Existing Franchises, Royalties, RBC Says - Marketscreener.com
RBC Capital Initiates Coverage of Alkermes (ALKS) with Sector Perform Recommendation - Nasdaq
S&P 500 Futures Drop in Premarket Trading; Alkermes, Intel Lead - Barron's
Alkermes initiated with a Sector Perform at RBC Capital - TipRanks
Charles Schwab Investment Management Inc. Sells 38,088 Shares of Alkermes plc (NASDAQ:ALKS) - Defense World
RBC Capital sets Alkermes stock target at $40, sees growth potential - Investing.com UK
Alkermes at Leerink’s Global Healthcare Conference: Strategic Pipeline Insights - Investing.com India
Alkermes at Leerink’s Global Healthcare Conference: Strategic Pipeline Insights By Investing.com - Investing.com South Africa
Alkermes to Participate in Upcoming Investor Conferences - GuruFocus.com
Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones - The Manila Times
Alkermes Plc to Host Earnings Call - ACCESS Newswire
Alkermes plc (NASDAQ:ALKS) Shares Bought by Smartleaf Asset Management LLC - Defense World
Proficio Capital Partners LLC Buys New Stake in Alkermes plc (NASDAQ:ALKS) - Defense World
(ALKS) Technical Pivots with Risk Controls - Stock Traders Daily
What is Zacks Research’s Estimate for Alkermes Q1 Earnings? - Defense World
Zacks Research Predicts Alkermes FY2027 Earnings - Defense World
UBS Group Upgrades Alkermes (NASDAQ:ALKS) to Neutral - MarketBeat
Y Intercept Hong Kong Ltd Invests $413,000 in Alkermes plc (NASDAQ:ALKS) - MarketBeat
UBS Upgrades Alkermes (ALKS) - Nasdaq
Bank of New York Mellon Corp Has $61.45 Million Stock Holdings in Alkermes plc (NASDAQ:ALKS) - Defense World
Alkermes (NASDAQ:ALKS) Upgraded to Neutral at UBS Group - Defense World
UBS Upgrades Alkermes to Neutral From Sell, $38 Price Target -March 04, 2025 at 08:27 am EST - Marketscreener.com
Alkermes upgraded to Neutral from Sell at UBS - TipRanks
Alkermes plc (ALKS): Among the Best Psychedelic Stocks to Buy in 2025 - Insider Monkey
New York State Common Retirement Fund Increases Holdings in Alkermes plc (NASDAQ:ALKS) - Defense World
Ieq Capital LLC Acquires New Stake in Alkermes plc (NASDAQ:ALKS) - MarketBeat
Alkermes VP Samuel Parisi sells $65,892 in shares - Investing.com India
Alkermes VP Samuel Parisi sells $65,892 in shares By Investing.com - Investing.com UK
Illinois Municipal Retirement Fund Sells 11,878 Shares of Alkermes plc (NASDAQ:ALKS) - MarketBeat
Alkermes plc (NASDAQ:ALKS) is HealthInvest Partners AB's 10th Largest Position - MarketBeat
C WorldWide Group Holding A S Purchases Shares of 250,000 Alkermes plc (NASDAQ:ALKS) - MarketBeat
Todd Asset Management LLC Sells 30,957 Shares of Alkermes plc (NASDAQ:ALKS) - MarketBeat
Sanctuary Advisors LLC Acquires 1,917 Shares of Alkermes plc (NASDAQ:ALKS) - Defense World
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Alkermes plc To Contact The Firm - ACCESS Newswire
Blue Trust Inc. Purchases 1,629 Shares of Alkermes plc (NASDAQ:ALKS) - Defense World
Alkermes Plc (ALKS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.46%
1.41%
자본화:
|
볼륨(24시간):